Clinical trials: Systemic Lupus
Systemic Lupus Erythematosus
Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus
Approximately 225 patients meeting study entry requirements will be enrolled and randomized (2:1, active versus placebo superimposed on background treatment) to R788 or placebo.
- Trial name
- SOLEIL (NCT00752999)
- Testing
- Fostamatinib Disodium (R935788)
- Sponsor
- Rigel Pharmaceuticals
Systemic Lupus Erthematosus (SLE)
2-HOBA in Systemic Lupus Erythematosus
This is a phase II randomized, placebo-controlled, double-blind, cross-over study to determine the effect of isolevuglandin (IsoLG) scavenging by 2-HOBA on blood pressure and immune activation in patients with SLE.
- Trial name
- NCT07225543
- Testing
- 2-HOBA acetate (2-Hydroxybenzlamine acetate)
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt University Medical Center
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of…
- Trial name
- VOYAGER (NCT00381810)
- Testing
- Rituximab, Methylprednisolone, Acetaminophen
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Systemic Lupus Erythematosus
Respiratory Function, Physical Activity and Fatigue in SLE
Increasing awareness of possible pulmonary involvement in patients with systemic lupus erythematosus (SLE) will enable earlier diagnosis of the disease and minimize damage accumulation.
- Trial name
- NCT07193745
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Melis Usul
Autoimmune Thrombocytopenia
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
This is a single-arm, open-label，phase I clinical study to evaluate the safety and tolerability of Inaticabtagene Autoleucel Injection in treatment of refractory systemic lupus erythematosus-related immune thrombocytopenia.
- Trial name
- NCT06826430
- Testing
- Inaticabtagene autoleucel Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Juventas Cell Therapy Ltd.
Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)
- Trial name
- NCT07583030
- Testing
- LVIVO-TaVec400 product
- Where
- 4 sites in China
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus
CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis
The purpose of this study is to evaluate the clinical efficacy of blisibimod as measured by a composite responder index in subjects who, despite corticosteroid use, continue to have seropositive, clinically-active Systemic Lupus…
- Trial name
- NCT02514967
- Testing
- Blisibimod
- Where
- 3 sites in Georgia
- Volunteers
- 3 people
- Sponsor
- Anthera Pharmaceuticals
Lupus Nephritis
Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil
The sponsor electively terminated the study because the risk mitigation measures, deemed necessary after an unforeseen safety event, could not be effectively implemented within this protocol while maintaining study timelines…
- Trial name
- NCT01369628
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EMD Serono
Systemic Lupus Erythematosus, Quality of Life
Health-related Quality of Life Measure in Pediatric Lupus
To examine the psychometric properties of a brief quality of life (QOL) instrument for use in pediatric systemic lupus erythematosus (SLE).
- Trial name
- NCT00280137
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Rutgers, The State University of New Jersey
SLE - Systemic Lupus Erythematosus
MB-CART19.1 in Refractory SLE
This is a phase l/ll open-label, multicentre, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE systemic lupus erythematosus.
- Trial name
- NCT06189157
- Testing
- MB-CART19.1
- Where
- 3 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Miltenyi Biomedicine GmbH
Nephritis, Lupus
Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone
lupus nephritis accounts for the most morbidity and mortality in patients with SLE. Glucocorticoids combined with cyclophosphamide (CYC) are effective for the treatment of patients with proliferative lupus nephritis and have been…
- Trial name
- NCT00268567
- Testing
- leflunomide combined with prednisone
- Where
- 8 sites in China
- Sponsor
- Peking University
Lupus Nephritis
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
- Trial name
- SIRIUS-LN (NCT05126277)
- Testing
- ianalumab s.c. q4w, ianalumab s.c. q12w
- Where
- 145 sites in United States, Argentina and 25 more
- Volunteers
- 452 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus
Several studies have shown that persons with systemic lupus erythematosus (SLE) have poor general health and a higher risk of heart attack and bone loss (osteoporosis) compared to the general population.
- Trial name
- NCT00188357
- Testing
- Education
- Where
- Canada
- Volunteers
- 360 people
- Sponsor
- University Health Network, Toronto
Systemic Lupus Erythematosus, Critical Illness
Accuracy, Feasibility and Acceptance of CGM Lupus
This is a prospective monocenter, non-randomised, open-lable single-group intervention diagnostic trial on the accuracy, reliability and feasibility of the continuous glucose monitoring system in critically systemic lupus…
- Conditions
- Systemic Lupus Erythematosus, Critical Illness, Diabetic Blood Glucose Monitoring
- Trial name
- NCT03296995
- Testing
- Flash glucose monitoring system
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in SLE Patients
Systemic lupus erythematosus (SLE) is a chronic inflammatory systemic autoimmune disease. Recurrent relapses of disease and development of long-term organ damage are two key unsolved clinical problems.
- Trial name
- NCT04515719
- Testing
- Belimumab
- Where
- China
- Volunteers
- 231 people
- Sponsor
- RenJi Hospital
Lupus Nephritis, Type 1 Diabetes Mellitus
Autologous Adoptive T Regulatory Cell Transfer in Autoimmune Diseases.
Investigators aim to develop an effective and safe treatment of autoimmune diseases through adoptive T regulatory cells transfer.
- Trial name
- NCT05566977
- Testing
- autologous adoptive T regulatory cell transfer.
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Ain Shams University
Systemic Lupus Erythematosus, Healthy Participants
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
This is a study to investigate the experimental medication BMS-986165 in healthy participants in order to study the effects it has on electrocardiogram results.
- Trial name
- NCT03541564
- Testing
- BMS-986165, Moxifloxacin
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Lupus Nephritis
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
The purpose of this study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus…
- Trial name
- AURORA 2 (NCT03597464)
- Testing
- Voclosporin
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Systemic Lupus Erythematosus
Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)
This is an exploratory open label single arm study to evaluate changes in disease activity and biomarkers in patients with mild active SLE, during treatment with ABR-215757 given as add-on to standard therapy.
- Trial name
- NCT00997100
- Testing
- paquinimod (ABR-215757)
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 13 people
- Sponsor
- Active Biotech AB
Fatigue, Systemic Lupus Erthematosus
Fatigue in Systemic Lupus Erythematosus
The aim of this study is to investigate the effects of biopsychosocial status, quality of life, functional status and hematological markers on fatigue in individuals with SLE.
- Trial name
- NCT06652256
- Where
- Turkey (Türkiye)
- Volunteers
- 39 people
- Sponsor
- Pamukkale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.